G6056 – Opiate(s), drug and metabolites, each procedure
HCPCS Level II code · G codes: Procedures / Professional Services (Temporary)
HCPCS codeG6056
- Long description
- Opiate(s), drug and metabolites, each procedure
- Short description
- Assay of opiates
- Pricing indicator
21Clinical Lab Fee Schedule – national limitation amount- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
T1HLab tests - other (Non-Medicare fee schedule)- Added
- January 1, 2015
- Last change
- January 1, 2016 – No change
- Termination date
- December 31, 2015
Frequently asked questions
What is HCPCS code G6056?
G6056 is a HCPCS Level II code for opiate(s), drug and metabolites, each procedure. It was discontinued on December 31, 2015.
Does Medicare cover G6056?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby G codes
- G6048 – Dimethadione
- G6049 – Epiandrosterone
- G6050 – Ethchlorvynol
- G6051 – Flurazepam
- G6052 – Meprobamate
- G6053 – Methadone
- G6054 – Methsuximide
- G6055 – Nicotine
- G6057 – Phenothiazine
- G6058 – Drug confirmation, each procedure
- G8126 – Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
- G8127 – Patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
- G8128 – Clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure
- G8395 – Left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function
- G8396 – Left ventricular ejection fraction (lvef) not performed or documented
- G8397 – Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.